"Despite Progress With CAR T-Cell Therapy, Transplant Retains Role in Myeloma" - Caroline Seymour
The influx of novel therapies into the multiple myeloma treatment armamentarium continues to challenge the role of transplant; however, Deepu Madduri, MD, assistant professor of medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai, explained that this approach is still recommended for eligible patients, as much remains unknown with chimeric antigen receptor (CAR) T-cell therapy. “If we feel that a patient is transplant-eligible, even if they do not necessarily want to do a transplant at that time, it’s important to harvest their stem cells and store them for the future, because you never know when you may need them,” said Dr. Madduri.
— Deepu Madduri, MD, Assistant Professor, Medicine, Hematology and Medical Oncology, Urology, Icahn School of Medicine at Mount Sinai